Allspring Global Investments Holdings LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 3.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,666 shares of the biopharmaceutical company’s stock after selling 1,269 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Regeneron Pharmaceuticals were worth $28,619,000 at the end of the most recent reporting period.
Other hedge funds have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Regeneron Pharmaceuticals by 92.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,694,308 shares of the biopharmaceutical company’s stock valued at $1,001,556,000 after buying an additional 813,967 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $136,678,000. Great West Life Assurance Co. Can bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $116,414,000. Thrivent Financial for Lutherans boosted its holdings in shares of Regeneron Pharmaceuticals by 499.0% during the 2nd quarter. Thrivent Financial for Lutherans now owns 123,413 shares of the biopharmaceutical company’s stock valued at $72,953,000 after buying an additional 102,809 shares in the last quarter. Finally, Ardevora Asset Management LLP bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $66,473,000. 84.25% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, CFO Robert E. Landry sold 183 shares of the stock in a transaction that occurred on Monday, March 27th. The shares were sold at an average price of $821.70, for a total value of $150,371.10. Following the completion of the sale, the chief financial officer now directly owns 32,929 shares of the company’s stock, valued at approximately $27,057,759.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 739 shares of the company’s stock in a transaction that occurred on Friday, February 3rd. The stock was sold at an average price of $764.50, for a total value of $564,965.50. Following the completion of the transaction, the chief financial officer now directly owns 32,105 shares in the company, valued at approximately $24,544,272.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robert E. Landry sold 183 shares of the company’s stock in a transaction that occurred on Monday, March 27th. The stock was sold at an average price of $821.70, for a total value of $150,371.10. Following the completion of the transaction, the chief financial officer now owns 32,929 shares of the company’s stock, valued at $27,057,759.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,786 shares of company stock valued at $22,950,981. 8.99% of the stock is owned by corporate insiders.
Regeneron Pharmaceuticals Price Performance
NASDAQ REGN opened at $822.09 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $538.01 and a 52 week high of $835.00. The firm has a market capitalization of $89.88 billion, a P/E ratio of 21.50, a PEG ratio of 2.41 and a beta of 0.23. The company has a quick ratio of 4.29, a current ratio of 5.06 and a debt-to-equity ratio of 0.12. The company has a 50-day moving average price of $767.53 and a 200-day moving average price of $743.00.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last released its earnings results on Friday, February 3rd. The biopharmaceutical company reported $12.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.18 by $4.38. The company had revenue of $3.41 billion during the quarter, compared to analyst estimates of $3.11 billion. Regeneron Pharmaceuticals had a net margin of 35.64% and a return on equity of 22.87%. The firm’s quarterly revenue was down 31.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $23.72 EPS. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 34.05 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts recently issued reports on REGN shares. Royal Bank of Canada dropped their price target on shares of Regeneron Pharmaceuticals from $806.00 to $802.00 in a research note on Monday, March 20th. Barclays upped their price target on shares of Regeneron Pharmaceuticals from $815.00 to $915.00 and gave the stock an “overweight” rating in a research note on Friday, March 24th. EF Hutton Acquisition Co. I upped their price target on shares of Regeneron Pharmaceuticals from $853.00 to $862.00 and gave the stock a “buy” rating in a research note on Thursday, March 23rd. Jefferies Financial Group upped their price target on shares of Regeneron Pharmaceuticals from $925.00 to $940.00 in a research note on Thursday, March 30th. Finally, Wells Fargo & Company upped their price target on shares of Regeneron Pharmaceuticals from $860.00 to $915.00 and gave the stock an “overweight” rating in a research note on Friday, March 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $840.57.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.
Featured Stories
Receive News & Ratings for Regeneron Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.